MOL #89250

Title

Defining the conformation of the estrogen receptor complex that controls estrogen induced apoptosis in breast cancer.

Ifeyinwa Obiorah, Surojeet Sengupta, Ramona Curpan and V. Craig Jordan

Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057 (I.O, S.S, V.C.J)

Institute of Chemistry, Romanian Academy, Timisoara, Romania (R.C)

1

MOL #89250

Running title page

Modulation of estrogen induced apoptosis

*Corresponding Author

V. Craig Jordan OBE, PhD, DSc, FMedSci

Scientific Director Georgetown Lombardi Comprehensive Cancer Center

Vincent T. Lombardi Chair of Translational Cancer Research

Vice Chair of Department of Oncology

Professor of Oncology and Pharmacology

Georgetown University Medical Center

3970 Reservoir Rd NW. Research Building, Suite E501, Washington, DC 20057

Tel: 202.687.2897

Fax: 202.687.6402

E-mail: vcj2@georgetown.edu

Text pages: 32

Number of figures: 8

Number of tables: 0

Number of words in abstract: 213

Number of words in introduction: 877

Number of words in discussion: 1413

Number of references: 47

Abbreviations

DES, diethylstilbestrol

E$_2$, 17β-estradiol;

ER, estrogen receptor;

4OHT, 4-hydroxytamoxifen;

RT-PCR, real time polymerase chain reaction;

TPE, triphenylethylene

TGF-α, transforming growth factor α

.

ABSTRACT

Development of acquired antihormone resistance exposes a vulnerability in breast cancer: estrogen induced apoptosis. Triphenylethylenes (TPEs) which are structurally similar to 4-hydroxytamoxifen (4OHT) were used for mechanistic studies of estrogen induced apoptosis. These TPEs all stimulate growth in MCF-7 cells but unlike the planar estrogens they block estrogen induced apoptosis in the long term estrogen deprived MCF7:5C cells. To define the conformation of the TPE:ER complex we employed a previously validated assay using the induction of transforming growth factor α (TGFα) mRNA *in situ* in MDA-MB 231 cells stably transfected with wild type ER (MC2) or D351G ER mutant (JM6). The assays discriminate ligand fit in the ER based on the extremes of published crystallography of planar estrogens or TPE antiestrogens. We classified the conformation of planar estrogens or angular TPE complexes as "estrogen-like" or "antiestrogen-like" complexes respectively. The TPE:ER complexes did not readily recruit the coactivator SRC3 or ER to the PS2 promoter in MCF-7 and MCF7:5C cells and molecular modeling showed that they prefer to bind to the ER in an antagonistic fashion i.e.: helix 12 not sealing the LBD effectively and therefore reduces critical SRC3 binding. The fully activated ER complex with helix 12 sealing the LBD is suggested to be the appropriate trigger to initiate rapid estrogen induced apoptosis.

INTRODUCTION

Estradiol (E_2) is a key stimulus of growth for estrogen receptor (ER) positive breast cancer. Endocrine therapy has been the gold standard of treatment in ER positive breast cancer(Jordan, 2009) but, acquired antihormone resistance to long-term antihormone therapy is a continuing clinical dilemma. Discovery of the evolution of acquired resistance exposed a vulnerability of cells by paradoxically triggering apoptosis with physiologic E_2 treatment(Jordan, 2004). Laboratory evidence demonstrates that E_2 is capable of inducing apoptosis in long term estrogen deprived MCF-7 cells (Lewis et al., 2005a, Lewis et al., 2005b). Similarly, tamoxifen-stimulated tumors (Osborne et al., 1987, Gottardis and Jordan, 1988) that develop in athymic nude mice in about a year will undergo regression after 5years of tamoxifen if exposed to physiologic E_2(Yao et al., 2000) .

Clinical data support the use of estrogens in the treatment of ER positive postmenopausal breast cancer. Synthetic high dose estrogens induced regression of tumors in postmenopausal women with advanced breast cancer in the first ever reported cancer chemical therapy (chemotherapy) mediated clinical study(Haddow et al., 1944). Clinical trials now exploit the concept for patients with metastatic breast cancer who develop resistance to endocrine therapy which shows that estrogens induce a partial to complete response in about 30 percent of postmenopausal breast cancer patients who had previous exhaustive antihormone therapy(Lønning et al., 2001, Ellis et al., 2009). A re-analysis(Anderson et al., 2012) of the Women Health Initiative estrogen alone trial(Anderson et al., 2004) which compared conjugated equine estrogen therapy with placebo in hysterectomised postmenopausal women showed a significant decrease in the incidence and mortality from breast cancer in these patients. The success of estrogen therapy in postmenopausal women depends on the menopausal status of the

patients. Women who are more than 5 years postmenopausal i.e. long term estrogen deprived, have better tumor remission rate as well as prevention from breast cancer (Obiorah and Jordan, 2013).

The ER is the key signal transduction pathway for breast cancer growth and apoptosis based on studies with competitive inhibition of E_2 action with antiestrogen (Lewis et al., 2005a, Maximov et al., 2011). The question to be addressed is how a series of estrogens with planar or angular structures can reprogram the estrogen-ER complex, to be either a survival signal in breast cancer or triggers apoptosis. We have previously classified estrogens(Jordan et al., 2001) based on reported data on the crystallization of the ligand binding domain (LBD) of the ER with estrogens (E2, DES) and antiestrogens (4OHT and raloxifene) (Brzozowski et al., 1997, Shiau et al., 1998) (See Fig 1). The planar estrogens are sealed within the LBD by helix 12, thus activating the AF2 domain which leads to coactivator binding and subsequent interaction of AF1 and AF2 (Tzukerman et al., 1994) to initiate growth and protein synthesis. In contrast, the bulky side chain of nonsteroidal anti-estrogen causes displacement of helix 12 and prevents coactivator binding to the AF2 resulting in anti-estrogenic action. Tamoxifen, a substituted triphenylethylene (TPE) derivative possesses estrogen-like activity (Harper and Walpole, 1966, Levenson et al., 1998, Macgregor and Jordan, 1998). We previously discovered that the surface amino acid D351 within the LBD is critical for the estrogenic actions of 4-hydroxytamoxifen (4OHT) (Schafer et al., 2000, Jordan et al., 2001). Unlike raloxifene, which is less estrogenic and possesses an anti-estrogen side chain that shields and neutralizes D351, the side chain in 4OHT is too short(Liu et al., 2002).

To interrogate the relationship of structure of an estrogenic ligand to program the conformation of the ER complex, we synthesized a range of estrogenic TPEs (Maximov et al.,

2010), which are structurally similar to 4OHT. We and others hypothesize that the structure of the ligand governs the external surface of the ER complex with either planar estrogens or the TPEs(McDonnell et al., 1995, Jordan et al., 2001). As a result of the ligand shape, the estrogens can program the conformation of the estrogen-ER complex to modulate rapid or delayed apoptosis. The growth response of the ER positive breast cancer cells is very sensitive to a wide range of estrogenic ligands. This is to ensure cancer cell survival in austere estrogen environments. This may not be true for estrogen induced apoptosis and the ligand shape may be required to be more specific to trigger cell death. The estrogen deprived cancer cell is protected.

We investigated the actions of clinically relevant planar estrogens (E_2, diethylstilbestrol, equilin, estrone and equilenin), anti-estrogens (4OHT, endoxifen. raloxifene and bazedoxifene) and model TPEs (bisphenol, trihydroxytriphenylethylene and ethoxytriphenylethylene) on growth in MCF-7 cells and apoptosis in MCF-7:5C cells. In order to understand the biological activity of the TPE:ER , we employed a validated ER engineered assay using induction of the mRNA for the transforming growth factor (TGF-α) gene *in situ* in MDA-MB231 cell stably transfected with wild type ER or mutant D351G:ER(Jordan et al., 2001) (Fig. 1). We classified the structure of the ligands based on their ability to initiate TGFα mRNA synthesis through the ER complex. The biological assay predicts two extremes of the ligand ER complex based on known X-ray crystallography (Brzozowski et al., 1997, Shiau et al., 1998): an "estrogen-like" shape and an "antiestrogen-like" shape. We find that the TPE:ER complex is antiestrogen-like which explains the delayed apoptosis in MCF7:5C cells compared to the estrogenic complex formed by the planar estrogens.

MATERIALS AND METHODS

Cell Culture and Reagents

Cell culture media were purchased from Invitrogen Inc. (Grand Island, NY) and fetal calf serum (FCS) was obtained from HyClone Laboratories (Logan, UT). Compounds 17β estradiol (E$_2$), diethylstilbesterol (DES), equilin, estrone, equilenin, ICI 182,780 and 4-hydroxytamoxifen (4OHT) were obtained from Sigma, St. Louis, MO and chemical structures are as previously described (Brzozowski et al., 1997, Shiau et al., 1998, Sawicki et al., 1999, Howell et al., 2000, Wang et al., 2009) . Raloxifene (ral) was a gift from Eli lilly (Indianopolis) and bazedoxifene (baze) was synthesized as previously described (Lewis-Wambi et al., 2011). The TPEs were synthesized as previously described(Maximov et al., 2010). MCF7:5C were derived from MCF7 cells obtained from the Drs. Bill McGuire and   Dean Edwards, San Antonio, Texas as reported previously(Jiang et al., 1992, Lewis et al., 2005b). MC2 and JM6 were obtained as previously described(Schafer et al., 2000). MCF7:WS8 cells were derived from the original MCF-7 wild type and were maintained in RPMI media supplemented with 10% FCS, 6 ng/ml bovine insulin and penicillin and streptomycin. These have been maintained for > 20 years. The MCF7 cells were cultivated in phenol red-free media containing 10% charcoal dextran treated FCS for 3 days prior to the start of the experiment. MCF7:5C cells were maintained in phenol-red free RPMI media containing 10% charcoal dextran treated FCS, 6ng/ml bovine insulin and penicillin and streptomycin. MC2 and JM6 cells were maintained in phenol red-free minimal essential medium supplemented with 5% 33 dextrancoated, charcoal-treated calf serum, 2 mM glutamine, 6 ng/ml bovine insulin, 100 units/ml penicillin/100 mg/ml streptomycin, nonessential amino acids, and 500 mg/ml G418.The cells were treated with indicated compounds for the specified time and were subsequently harvested for tissue culture experiments.

Cell growth assay

The cell growth was monitored by measuring the total DNA content per well in 24 well plates.

Fifteen thousand cells were plated per well and treatment with indicated concentrations of compounds was started after 24 hours, in triplicates. Media containing the specific treatments were changed every 48 hours. On day 7, the cells were harvested using hypotonic buffer solution and were subsequently sonicated. The DNA content was assessed using a fluorescent DNA quantitation kit (Cat # 170-2480; Bio-Rad,Hercules, CA, USA) and was performed as previously described (Lewis et al., 2005a).

Annexin V Analysis of Apoptosis

The annexin V – FITC-labeled Apoptosis Detection Kit I (Pharmingen, San Diego, CA) was used to detect and quantify apoptosis by flow cytometry according to the manufacturer's instructions. In brief, MCF-7:5C cells (1×10^6 cells/mL) were seeded in 100-mm dishes and cultured overnight in estrogen-free RPMI 1640 medium containing 10% SFS. The next day, cells were treated with <0.1% ethanol vehicle (control), estradiol (1 n M),TPEs (1 μM) or SERMs (1 μM) for 72 hours and then harvested in cold PBS (Invitrogen) and collected by centrifugation for 10 min at $500 \times g$. Cells were then resuspended and stained simultaneously with FITC-labeled annexin V and propidium iodide (PI). Cells were analyzed using a fluorescence-activated cell sorter (FACS) flow cytometer (Becton Dickinson, San Jose, CA).

RNA isolation and real time PCR

Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) and RNAeasy kit according to the manufacturer's instructions. Real-time PCR was performed as previously described(Sengupta et al., 2010). Briefly, High capacity cDNA reverse transcription kits (Applied Biosystems, Foster City, CA) was used to generate cDNA was using 1 μg of total RNA in a total volume of 20 μl. The cDNA was subsequently diluted to 500 μl and RT-PCR was performed using ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster

City, CA). In each well 20 ul reaction volume included 10μl SYBR green PCR master mix (Applied Biosystems, Foster City, CA), 125 nM each of forward and reverse primers and 5 μl of diluted cDNA. RT-PCR was performed using specific primers as previously described(Sengupta et al., 2013) and the change in expression of transcripts was determined and the ribosomal protein 36B4 mRNA was used as the internal control.

Transforming growth factor assay

Three hundred thousand MDA-MB231 cells stably transfected with wild type ER (MC2) or mutant D351ER were seeded in six well plates and treated with either vehicle control or various concentrations of planar estrogens, triphenylethylenes or antiestrogens after 24h. After 24h, the cells were harvested for mRNA and RT-PCR was performed to quantify TGFα mRNA levels as mentioned previously. The assay elucidates the putative conformation of ligand-receptor complex in relation to apoptotic inducing action of the ligands (Fig.1).

Immunoblotting

Proteins were extracted in cell lysis buffer (Cell Signaling Technology, Beverly, MA) supplemented with Protease Inhibitor Cocktail (Roche, Indianapolis, IN) and Phosphatase Inhibitor Cocktail Set I and Set II (Calbiochem, San Diego, CA). Total protein content of the lysate was determined by a standard BCA assay using the reagent from Bio-Rad Laboratories (Hercules, CA). Twenty five micrograms of total protein was separated on 10% sodium dodecyl sulfate (SDS) polyacrylamide gel and transferred to a nitrocellulose membrane. The membrane was probed with primary antibodies followed by incubation with secondary antibody conjugated with HRP and reaction with Western Lighting™ plus-ECL enhanced chemiluminescent substrate

(PerkinElmer Inc., Waltham MA). Protein bands were visualised by exposing the membrane to X-ray film.

Chromatin immunoprecipitation (ChIP) assay

ChIP assay was performed as described previously(Maximov et al., 2011). Briefly, cells were treated with indicated compounds for 45 min and cross-linked using 1.25% paraformaldehyde for 15 min and subsequently stopped cross-linking with 2 M glycine. Cells were collected, followed by nuclei isolation by centrifugation. Isolated nuclei were resuspended in SDS-lysis buffer followed by sonication and centrifugation at 14 000× g for 20 min at 4°C. The supernatant were diluted 1: 10 with ChIP dilution buffer. Normal rabbit IgG and Magna ChIP protein A magnetic bead (Upstate Cell Signaling Solutions, Temecula CA, USA) were used to immunoclear the supernatant followed by immunoprecipitation with antibodies against ERα (1:1 mixture of cat# sc-543 and sc-7207; Santa Cruz Biotechnology Inc., Dallas, TX, USA) and steroid receptor coactivator-3 (SRC3) (cat# 13066; Santa Cruz Biotechnology, Inc. Dallas, TX, USA). Immunocomplexes were pulled down using protein A magnetic beads and a magnet. The beads bound to immunocomplexes were washed using different buffers as described(Maximov et al., 2011). Precipitates were finally extracted twice using freshly made 1% SDS and 0.1 M $NaHCO_3$ followed by de-crosslinking. The DNA fragments were purified using Qiaquick PCR purification kit (Qiagen, Valencia, CA, USA). RT-PCR was performed using 2 μl isolated DNA, using primers specific for *PS2* promoter(Maximov et al., 2011). The data are presented as percent input of starting chromatin input after subtracting the percent input pull down of the negative control (normal rabbit IgG).

Molecular modeling

The molecular modeling study was performed using the available X-ray crystallographic structures of ERα in the agonist and antagonist conformations. The 3D coordinates of ERα co-crystallized with E2 (1GWR) and 4OHT (3ERT) were extracted from RCSB Protein Data Bank (PDB)(Supplementary figures 6-9) (Berman et al., 2000). The ligand was prepared for docking using the LigPrep utility (LigPrep 2.5; Schrodinger, LLC, Portland, OR, 2011). Protein preparation workflow (Schrodinger, LLC, New York, NY, 2011) was employed to prepare the proteins for molecular docking. The residues well-known to be important for biological activity D351 and E353 were kept charged in both receptors, the free rotation of hydroxyl group for T347 was allowed and H524 residue was protonated at the epsilon nitrogen atom based on the available literature data. Glide software (Glide 5.7; Schrodinger, LLC Portland, OR, 2011) was used for molecular docking and the best docking poses were selected based on the composite score, Emodel, which accounts not only for the binding affinity but also for the energetic terms, such as ligand strain energy and interaction energy

RESULTS

Growth effects of estrogens and anti-estrogens in MCF-7 cells

To study the biological activity of the planar estrogens (Fig.2A) which include E_2, DES, equilin, estrone and equilenin), and triphenylethylenes (Fig.2B) namely, EtOX (ethoxytriphenylethylene), 3OHTPE (trihydroxytriphenylethylene) and bisphenol, we tested their ability to induce cell proliferation in wild type MCF-7cells. As controls we used SERMs; 4OHT, endoxifen (endox), raloxifene (ral) and bazedoxifene (baze) (Fig.2C) which are known anti-

estrogens. MCF-7 cells were grown in estrogen free media for 3 days and treated with various concentrations of the indicated compounds and their effects were compared to E_2. All planar estrogens (Fig. 3A) were able to induce cell proliferation in a concentration dependent manner to the maximum level as E_2. DES, equilin and estrone induced cell proliferation with maximum stimulation occurring at 0.1nM, whereas equilenin reached maximal stimulation at 1nM as compared to 0.01nM for E_2. Similarly, the triphenylethylenes tested were able to induce cell growth to the maximum level as E_2, although their agonistic potency was less than E_2 (Fig. 3B). Bisphenol, EtOX and 3OHTPE all induced cell proliferation in a concentration dependent manner with maximum stimulation at 1-10 nM as compared to 0.01 nM for E_2. Nonetheless, the TPEs all were potent estrogen-agonists in this assay. On the other hand, as expected, the SERMs, 4OHT, endox, ral and baze (Fig. 3C) which are antiestrogens did not induce cell growth.

Effects of planar estrogens, TPEs and SERMS on apoptosis in MCF7:5C cells

We tested if TPEs and SERMS were able to induce apoptosis in long term estrogen deprived MCF7:5C breast cancer cells as effectively as E_2. All planar estrogens were able to cause growth inhibition as effectively as E_2 (Fig.4A). All the planar estrogens achieved maximal growth inhibition in the range of 1 nM as compared to E_2 which achieved maximal growth at 0.1 nM. To confirm that the decrease in cell proliferation was due to apoptosis, MCF-7:5C cells were treated with ethanol vehicle (control) E_2 (1nM), or DES (1nM),equilin(1nM), estrone(1nM) and equilenin(1nM) for 72 hours, and annexin V – FITC and PI fluorescence was determined by flow cytometry. In the control-treated group, only 5.9% stained positive for apoptosis, whereas, in the E_2 treated group (Supplemental Figure 1A), cells that stained positive for apoptosis increased by 3 fold. Interestingly, the estrogenic triphenylethylenes did not inhibit the growth of

MCF7:5C cells even at higher concentrations (Fig.4B) at the end of a 7 day assay. Compared to E_2, bisphenol, 3OHTPE and EtOX did not show any effective apoptosis even at micro-molar concentration (Supplemental Figure 1B) and were comparable to that of the SERMs (Fig 4C). Furthermore, the TPEs were able to block E_2 mediated apoptosis in a similar manner to the SERMs (Fig. 4D-E). However, the TPEs were able to induce apoptosis after 14 days of treatment (Fig.4F), whereas the SERMs still did not induce apoptosis in the MCF7:5C cells (Supplemental Figure 1C).

Regulation of transforming growth factor alpha (TGFα) gene by planar and non-planar estrogens in MDA: MB-231 cells stably transfected with wild type ERα or D351G mutant ERα.

The TGFα gene is induced by 4OHT as effectively as E_2 in MDA:MB-231 cells stably transfected with wild type ERα (MC2 cells). In contrast, in MDA:MB-231 cells stably transfected with a mutant D351ER (JM6 cells), 4OHT fails to induce expression of the TGFα gene but E_2 retains its ability to induce the TGFα gene. We determined if the TPEs (3OHTPE, EtOX and bisphenol) and the planar estrogens (DES, equilin, estrone and equilenin) resembled E_2 or 4OHT in inducing the TGFα gene expression by using the assay system summarized in Fig. 1). As expected, all the planar estrogens were able to induce TGFα gene expression in a concentration dependent manner in both wild type ERα (MC2) (Fig. 5A) and D351G mutant ERα (JM6) cells (Fig. 5D). On the other hand, the TPEs and tamoxifen metabolites; 4OHT and endox were able to induce TGFα gene expression in MC2 cells (Fig. 5B) in a concentration dependent manner, whereas ral and baze do not activate the TGFα gene in this cell line (Fig. 5C). By contrast, the TPEs, 4OHT and endox distinctly failed to induce TGFα gene expression (Fig.

5E) in JM6 cells which expresses D351G mutant form of the ERα, rather they block E_2 mediated TGFα induction(Fig. 5F). Similarly, ral and baze are antiestrogenic in the mutant stable transfectant. These findings indicate that the TPEs possess antiestrogenic properties and binds with ERα in a manner which is distinctly different from the planar estrogens but strikingly resembles 4OHT and endox.

Recruitment of ERα (estrogen receptor α) and SRC3 (steroid co-activator-3) at the proximal promoter of PS2 gene after treatment with triphenylethylenes

To further understand the ER mediated mechanism involved in the regulation of the model estrogen responsive gene PS2 by the TPEs in MCF7:WS8 and MCF7:5C cells we determined the recruitment of the ERα and SRC-3 protein at the proximal promoter of PS2 gene, which has a classical estrogen responsive element (Fig. 6A), using ChIP (chromatin immunoprecipitation) assay after 45 minutes of treatment with TPEs (1 µM) and compared it with E_2 (1nM) and 4OHT (1µM). The whole assay was repeated two further times with similar results occurring in each cell line (Supplemental Figures 4-5). In MCF7:WS8 cells, E_2 was able to recruit very high level of ERα at the PS2 promoter (Fig. 6B) where more than 8% of input PS2 promoter region was occupied by ERα. On the other hand TPEs were ~50% as efficient as E_2 treatment in terms of recruiting ERα whereas very low level (~20% of E_2) of ERα recruitment was observed after 4OHT treatment. Recruitment of the co-activator SRC3, which is critical in inducing the estrogen responsive gene, was not observed at all after 4OHT treatment at the PS2 promoter. All the TPEs tested recruited only about 15-20% of SRC3 as compared to E_2 treatment, which showed around 0.9 % of input PS2 promoter region was occupied by SRC3 protein. Interestingly, in MCF7:5C cells treated with E_2, around 5% of input PS2 promoter region was occupied by ERα (Fig. 6C). In MCF7:5C cells treated with TPEs had 50% less ERα occupancy

15

and ~80% less SRC3 occupancy was observed as compared to E2 treatment in MCF7:5C cells, whereas no SRC3 recruitment was observed after 4OHT treatment. These ChIP data concurs with the PS2 mRNA induction level in MCF7:WS8 and MCF7:5C cells with their respective treatments (Supplemental Figure 2A-B).

Induction of ERα expression by planar and non-planar estrogens

To test whether the structure the compounds create with the ER affects the ERα expression levels, 4 breast cancer cell lines, which include MCF-7:WS8, MCF7:5C, MC2 and JM6 cells, were treated with planar estrogens (1nM), TPEs (1µM) and SERMs (1µM)for 24h and ERα levels were determined by western blotting. ICI was included as a positive control. All planar estrogens and ICI caused decrease in the ERα protein levels in MDA-MB231 cells stably transfected with either wild type ER (MC2) (Fig. 7A) or with the mutant receptor (JM6) (Fig. 7B). On the other hand, the TPEs do not decrease the ERα protein levels in the MC2 cells, whereas 4OHT and endox cause accumulation of the receptor, while ral and baze cause moderate down regulation of the ER. In the JM6 cells, all TPEs and SERMs did not dramatically affect the ERα protein expression. As expected, all planar estrogens and ICI cause a decrease of ERα protein levels in MCF7:WS8 (Fig. 7C) and MCF7:5C (Fig. 7D) cells, whereas the tamoxifen metabolites caused increase in ERα protein expression. Interestingly the TPEs cause moderate decrease of ERα in MCF7:WS8 and MF7:5C cells compared to E2, and the reduction is more dramatic in the MCF7:5C cells. In contrast to the tamoxifen metabolites, ral and baze also cause a reduction in the protein levels of ERα in both MCF-7 derived breast cancer cell lines. ER α protein levels of all breast cancer cell lines used in the study are compared in Supplemental Figure 3.

Binding of Bisphenol to the LBD of ER alpha

Next, the binding mode of the TPEs was investigated by the molecular docking of bisphenol to the ligand binding domain (LBD) of ERα.Thus the flexible docking of bisphenol into the LBD of the receptor co-crystallized with E_2 and 4OHT (Fig. 8A-B) were performed. The superimposition of the top ranked docking pose of the ligand onto the E_2 co-crystallized with ERα, agonist conformation of the receptor, shows some incompatibility (Fig.8C). Hence the resulting model revealed sterical clashes between bisphenol and "Leu crown", mostly with the side chains of Leu525 and Leu540. Due to this steric hindrance it is most unlikely for bisphenol to bind in a conformation of ERα that is similar to that of E_2. On the other hand, when bisphenol is docked into the binding site of 4OHT co-crystallized with ERα (Fig. 8D), the binding mode is similar to that of 4OHT.Namely the same alignment of the ligand in the binding pocket is noticed having the propensity to form the same hydrophobic contacts with the amino acids lining the binding cavity and to recapitulate the complex H-bond network involving E353, R394 and highly order water molecule. Taken together, this data show that bisphenol and extrapolating TPEs would most likely bind to the ERα in the antagonist conformation of the receptor.

DISCUSSION

Estrogens are potent mitogens for the proliferation of breast cancer cells. In contrast, planar estrogens (class 1) can induce apoptosis of long term estrogen deprived MCF-7 cells (MCF7:5C) in a paradoxical manner. 4OHT has no effect in the MCF: 5C cells but rather blocks E_2 mediated apoptosis (Maximov et al., 2011). TPEs which are structurally similar to 4OHT possess estrogenic properties in the MCF-7 cells at comparable concentrations to the planar estrogens.

The TPEs (class II angular estrogens) do not rapidly trigger estrogen induced apoptosis in MCF7:5C cells, but block class 1 planar estrogen induced apoptosis. However, prolonged treatment with the TPEs lead to an eventual induction of apoptosis in the MCF7:5C cells, whereas the cells continue to be resistant to the actions of the SERMs which are known antiestrogens (Supplemental Figure 1C). As a result of these aforementioned findings we initially proposed a hypothesis(Maximov et al., 2011), that the TPE-ER complex mimics of an anti-estrogen-ER complex and this may be responsible for the delay of apoptosis by the TPEs. We addressed the hypothesis in four ways: utilizing our validated functional assay to classify estrogens using the induction of the TGFα gene (Jordan et al., 2001)(Fig. 1), binding of ER and recruitment of SRC3 to the promoter region of a model estrogen response gene (PS2) (Fig. 6), ligand bound ER accumulation or reduction and putative ER docking experiments(Fig. 8).

We have previously demonstrated the critical importance of D351 in modulating the SERM:ER complex (Levenson et al., 2001) for the estrogen-like actions of the 4OHT by removing the exposed surface charge by engineering a mutant ER D351G, which causes a conversion of the 4OHT:ER from being estrogenic to completely antiestrogenic at the TGFα gene (Levenson et al., 1998, Schafer et al., 2000). The anchoring role of D351 in the activation of the helix 12 mutated ER has recently (Merenbakh-Lamin et al., 2013, Toy et al., 2013) been illustrated in tissue from metastatic breast cancer resistant to anti-hormones. Mutations of Y537 in helix 12 are shown to anchor to D351 to accomplish sealing of the unoccupied LBD by helix 12. This provides evidence of the clinical relevance of our assay system.

To determine whether the conformation of the ER complex determines the triggering of apoptosis in long term estrogen deprived ER positive breast cancer cells, MCF-7:5C, we employed (Jordan et al., 2001) an assay using induction of the mRNA for the TGF-α gene *in situ*

in MDA-MB-231 cells stably transfected with cDNA wild-type(MC2) or D351G ER(JM6). As expected, all planar estrogens cause activation of the TGFα gene in the MC2 and JM6 cells. The planar estrogens are not affected by the mutation on D351 because upon binding to the ER, they are sealed within the LBD by helix 12 allowing for coactivator binding on the surface of helix 12 (AF-1) and gene activation. The TPEs induce TGFα gene at comparable concentrations as the tamoxifen metabolites, 4OHT and endox in the MC2 cells (Fig. 5B), but lose this estrogen-like action in the JM6 cells (Fig. 5E) and block E_2 induction of TGFα (Fig. 5F). The results of the TGF assay imply that TPEs adopt a 4OHT-like conformation with the ER with helix 12 pushed back and D351 exposed. By inference the "antiestrogenic conformation" of the TPE: ER complex is responsible for the initial inhibition of E_2 induced apoptosis. The short aminoethoxy side chain of the tamoxifen metabolites(Schafer et al., 2000) and the absence of this side chain in the TPEs prevent adequate shielding of the charged D351, whereas the anti-estrogenic side chain of ral and baze provides effective interaction and neutralization of this charge(Liu et al., 2002) (Fig. 5C). Thus, this prevents the induction of the TGFα gene by ral and baze.

SRC3 has been shown to be extremely important in estradiol induced growth in breast cancer cells (Font de Mora and Brown, 2000, List et al., 2001, Lahusen et al., 2009). Additionally, SRC3 knockdown was found to reduce apoptosis induced by E_2 in MCF7:5C cells(Hu et al., 2011). Using ChIP assays we show that TPEs are able to recruit ERα but less efficiently when compared to E_2 and this was further observed with SRC3 (Fig. 6).The ER:TPE complex binds to the promoter with about 50% of E_2 but SRC3 binding is <25% of E_2. This suggests that treatment with TPEs influences the conformation of the liganded-ERα complex such that efficiency of ERα binding to ERE region is moderately inhibited whereas binding of SRC3 is severely inhibited as compared to E_2 treatment which is a planar estrogen. This may also

explain why bisphenol is a partial agonist at the prolactin gene and exhibits antiestrogen properties (Jordan and Lieberman, 1984a, Jordan et al., 1984b). Of notable importance, the magnitude of SRC3 recruitment by the TPEs is far less in MCF7:5C cells (Fig. 6C) when compared to MCF7:WS8 cells (Fig. 6B) and may play a crucial role in manifesting the functional role of the TPEs in these cells. This observation may contribute to the robust cell replication in MCF-7 with TPEs but delayed apoptosis in MCF7:5C.

Estradiol induces downregulation of the ER in breast cancer cells (Borras et al., 1994, Borras et al., 1996, Reid et al., 2003)and this process is inhibited by 4OHT, thereby causing accumulation of ER-α(Wijayaratne et al., 1999). Similarly in all our cell lines, the planar estrogens all downregulate the ER while tamoxifen metabolites, 4OHT and endox, do not (Fig. 7). The western blot analysis shows that the TPEs do not readily decrease ERα protein levels when compared to the planar estrogens. This illustrate the fact that the TPE:ER complex appears to be "antiestrogen-like" when compared to 4OHT and endox (Fig. 7) However in the MCF7:5C cells, their ability to downregulate ERα protein levels is more apparent. The ER complex resembles the vehicle (control) rather than the extremes of E2 or 4OHT. Ral and baze also cause moderate decrease in ERα levels which concurs with previous studies done on these compounds(Lewis-Wambi et al., 2011). Bourgon-Voillard and colleagues (Bourgoin-Voillard et al., 2010) determined that class II ligands such as bisphenol had less tendency to promote recruitment of coactivators containing LxxLL motif and this appeared to be a requirement for the downregulation of the ER in MCF7 cells. Bourgoin-Voillard and colleagues (Bourgoin-Voillard et al., 2010) also illustrate the accumulation of the bisphenol:ER complex in MCF-7 cells using immunocytochemistry.

The molecular modeling data (Fig. 8) provide evidence that the TPEs bind to the ERα in

a manner similar to that observed with 4OHT using x-ray crystallography. The bulky phenyl ring of the TPEs prevent helix 12 from sealing the LBD and will result in an initial steric hindrance when attempting to bind in the E_2-ER α conformation, resulting in their blockade of E_2 induced apoptosis. However, continuous treatment of the MCF7:5C with the TPEs for 14 days result in induction of apoptosis similar to the planar estrogens. This suggests that the antiestrogenic conformation the TPEs create with the ER prevents immediate coactivator binding, causing a delay in the trigger for apoptosis but this delay disappears with prolonged treatment. This conclusion correlates with the Haddow clinical study(Haddow et al., 1944), where postmenopausal women with advanced breast cancer were treated with TPE- like estrogens leading to about a 30% response rate during breast cancer therapy. The planar estrogens form compact estrogen-ER complex with excellent SRC3 binding and recruitment and it appears that this event is necessary to induce apoptosis in the MCF7:5C cells. On the other hand, angular TPEs form antiestrogen-like-ER complex with less SRC3 binding and recruitment, thereby leading to delayed apoptosis, whereas the SERMS do not recruit SRC3 so this results in no apoptosis.

In conclusion, we have advanced the hypothesis that TPE-ER conformation is initially similar to that of tamoxifen metabolites, 4OHT and endox and our molecular classification assay indicate that helix 12 is pushed back in the TPE-ER complex. The antiestrogenic conformation of the TPE-ER complex appears to be responsible for the initial blocking of apoptosis and reduction in coactivator recruitment observed with the TPEs in the MCF7:5C cells. It is important to stress that the evidence we present suggests that the TPE:ER complex conformation may in fact be in between the extreme structures of E_2:ER and 4OHT:ER ligand binding domain (Brzozowski et al., 1997, Shiau et al., 1998). Since prolonged treatment with TPEs causes

MOL #89250

triggering of ER mediated apoptosis similar to that of the planar estrogens but 4OHT does not,

an intermediate conformation of the TPE:ER complex may be responsible for these observations.

Authorship Contributions

Participated in research design: Obiorah I, Sengupta S, and Jordan V.C.

Conducted experiments: Obiorah I, Sengupta S, Curpan R.

Performed data analysis: Obiorah I Sengupta S, Curpan R and Jordan V.C.

Wrote or contributed to the writing of the manuscript: Obiorah I, Curpan R and Jordan V.C.

REFERENCES

Anderson G, Chlebowski R, Aragaki A, Kuller L, Manson J, Gass M, Bluhm E, Connelly S, Hubbell F, Lane D, Martin L, Ockene J, Rohan T, Schenken R, Wactawski-Wende J (2012) Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. *Lancet Oncol* **13**:476-486.

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* **291**:1701-1712.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. *Nucleic Acids Res* **28**:235-242.

Borras M, Hardy L, Lempereur F, el Khissiin AH, Legros N, Gol-Winkler R, Leclercq G (1994) Estradiol-induced down-regulation of estrogen receptor. Effect of various modulators of protein synthesis and expression. *J Steroid Biochem Mol Biol* **48**:325-336.

Borras M, Laios I, el Khissiin A, Seo HS, Lempereur F, Legros N, Leclercq G (1996) Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells. *J Steroid Biochem Mol Biol* **57**:203-213.

Bourgoin-Voillard S, Gallo D, Laïos I, Cleeren A, Bali LE, Jacquot Y, Nonclercq D, Laurent G, Tabet J-C, Leclercq G (2010) Capacity of type 1 and 11 ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif—Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells. *Biochem Pharmacol* **79**:746-757.

Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson J-A, Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature* **389**:753-758.

Ellis M, Gao F, Dehdashti F, Jeffe D, Marcom P, Carey L, Dickler M, Silverman P, Fleming P, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel B (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor–positive, aromatase inhibitor–resistant advanced breast cancer: A phase 2 randomized study. JAMA **302**:774-780.

Font de Mora J, Brown M (2000) AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor. *Mol Cell Biol* **20**:5041-5047.

Gottardis MM, Jordan VC (1988) Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res **48**:5183-5187.

Haddow A, Watkinson JM, Patterson E, Koller PC (1944) Influence of synthetic oestrogens upon advanced malignant disease. . *BMJ* **2**:393-398.

Harper MJ, Walpole AL (1966) Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. *Nature* **212**:87.

Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182,780 (Faslodex™). Cancer 89:817-825.

Hu ZZ, Kagan BL, Ariazi EA, Rosenthal DS, Zhang L, Li JV, Huang H, Wu C, Jordan VC, Riegel AT, Wellstein A (2011) Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells. *PLoS ONE* **6**:27.

Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol **90**:77-86.

Jordan VC (2004) Selective estrogen receptor modulation: concept and consequences in cancer. *Cancer Cell* **5**:207-213.

Jordan VC (2009) A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res **69**:1243-1254.

Jordan VC, Lieberman ME (1984a) Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. *Mol Pharmacol* **26**:279-285.

Jordan VC, Lieberman ME, Cormier E, Koch R, Bagley JR, Ruenitz PC (1984b) Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro. *Mol Pharmacol* **26**:272-278.

Jordan VC, Schafer JM, Levenson AS, Liu H, Pease KM, Simons LA, Zapf JW (2001) Molecular classification of estrogens. *Cancer Res* **61**:6619-6623.

Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT (2009) The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. *Breast Cancer ResTreat* **116**:225-237.

Levenson AS, MacGregor Schafer JI, Bentrem DJ, Pease KM, Jordan VC (2001) Control of the estrogen-like actions of the tamoxifen–estrogen receptor complex by the surface amino acid at position 351. *J Steroid Biochem Mol Biol* **76**:61-70.

Levenson AS, Tonetti DA, Jordan VC (1998) The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. *Br J Cancer* **77**:1812-1819.

Lewis-Wambi JS, Kim H, Curpan R, Grigg R, Sarker MA, Jordan VC (2011) The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. *Mol Pharmacol* **80**:610-620.

Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Jordan VC (2005a) Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst **97**:1746-1759.

Lewis JS, Osipo C, Meeke K, Jordan VC (2005b) Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. *J Steroid Biochem Mol Biol* **94**:131-141.

List H-J, Lauritsen KJ, Reiter R, Powers C, Wellstein A, Riegel AT (2001) Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 Is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. *J Biol Chem* **276**:23763-23768.

Liu H, Park W-C, Bentrem DJ, McKian KP, Reyes ADL, Loweth JA, Schafer JM, Zapf JW, Jordan VC (2002) Structure-Function Relationships of the Raloxifene-Estrogen Receptor-α

Complex for Regulating Transforming Growth Factor-α Expression in Breast Cancer Cells. *J Biol Chem* **277**:9189-9198.

Lønning P, Taylor P, Anker G, Iddon J, Wie L, Jorgensen LM, Mella Q, Howell A (2001) High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. *Breast Cancer ResTreat* **67**:111-116.

Macgregor JI, Jordan VC (1998) Basic Guide to the Mechanisms of Antiestrogen Action. *Pharmacol Rev* **50**:151-196.

Maximov P, Sengupta S, Lewis-Wambi JS, Kim HR, Curpan RF, Jordan VC (2011) The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: a hypothesis. *Horm Mol Biol Clin Investig* **5**:27-34.

Maximov PY, Myers CB, Curpan RF, Lewis-Wambi JS, Jordan VC (2010) Structure–function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. *J Med Chem* **53**:3273-3283.

McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW (1995) Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 9:659-669.

Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R, Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I (2013) D538G Mutation in Estrogen Receptor-α: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer. *Cancer Res* doi:101158/0008-5472   .CAN-13-1197 [epub].

Obiorah I, Jordan VC (2013) 2012 NAMS/PFIZER- Wulf H. Utian endowed lecture. The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in

postmenopausal women that causes a reduction in breast cancer incidence and mortality. *Menopause* **20**:372-382.

Osborne CK, Coronado EB, Robinson J (1987) Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol **23**:1189-1196.

Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J, Gannon F (2003) Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. *Mol Cell* **11**:695-707.

Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D (1999) Structure of the ternary complex of human 17β-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proceedings of the National Academy of Sciences 96:840-845.

Schafer JM, Liu H, Bentrem DJ, Zapf JW, Jordan VC (2000) Allosteric Silencing of Activating Function 1 in the 4-Hydroxytamoxifen Estrogen Receptor Complex Is Induced by Substituting Glycine for Aspartate at Amino Acid 351. *Cancer Res* **60**:5097-5105.

Sengupta S, Obiorah I, Maximov PY, Curpan R, Jordan VC (2013) Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells. *British J Pharmacol* **169**:167-178.

Sengupta S, Sharma CG, Jordan VC (2010) Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Investig **2**:235-243.

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. *Cell* **95**:927-937.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439-1445.

Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. *Mol Endocrinol* **8**:21-30.

Wang Z, Wijewickrama GT, Peng KW, Dietz BM, Yuan L, van Breemen RB, Bolton JL, Thatcher GR (2009) Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus. J Biol Chem 284:8633-8642.

Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, McDonnell DP (1999) Comparative analyses of mechanistic differences among antiestrogens. *Endocrinol* **140**:5828-5840.

Yao K, Lee E, Bentrem D, England G, Schafer J, O'Regan R, Jordan V (2000) Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res **6**:2028-2036.

Footnotes

This work has been presented as a poster at the Lombardi research days, at Georgetown University Medical Center, March 7TH 2012 and at the AACR Annual Meeting 2012 in Chicago, IL, April 6-13, 2012.

LEGENDS FOR FIGURES

Fig.1. Functional Test: Putative conformations of the complex with ligand in LBD for Type II estrogen to be "antiestrogenic" with regard to helix 12 positioning. The assay discriminates between ligands (A) which allow helix 12 to seal the LBD or not (B) and (C). Sealing of helix 12 over the LBD is important for the ability of the ligands to trigger apoptosis.

Fig.2. Chemical structures of the compounds used in the experiments. (A) Planar estrogens **(B)** Triphenylethylenes **(C)** Selective estrogen receptor modulators.

Fig.3. Growth characteristics of planar estrogens and triphenylethylenes in MCF7:WS8 cells.
MCF7:WS8 cells were seeded in 24-well plate and treated with **(A)** planar estrogens over a range of doses for seven days. Cell growth was assessed as DNA content in each well. Induction of cell growth by **(B)** Triphenylethylenes and **(C)** SERMs was assessed in comparison to E_2. Each data point is average +/- SD of three replicates.

Fig.4. Differential effect of planar estrogens and triphenylethylenes in MCF7:5C cells. Dose dependent effect of **(A)** planar estrogens **(B)** Triphenylethylenes and **(C)** SERMs on apoptosis of MCF7:5C cells treated for 7 days as indicated. Cells were treated with 1nM 17-β estradiol (E_2) in presence of increasing concentration of indicated TPEs **(D)** and SERMs **(E)**. **(F)** Effect of TPE in MCF7:5C cells after 14 days of treatment. Each data point is average +/- SD of three replicates.

Fig.5. The concentration-dependent action of test compounds using wild type(MC2) and mutant D351G ER (JM6) stable transfectants.

MC2 cells were treated with **(A)** planar estrogens **(B)** TPEs, 4OHT and endox for 24h at indicated concentrations and expression of TGFα RNA was measured using quantitative real time PCR. **(C)** MC2 cells treated with ral and baze in a dose responsive manner. JM6 cells were treated with **(D)** planar estrogens (**E)** E_2, TPEs, active metabolites of tamoxifen (4OHT and endox) for 24 h with various concentrations and expression of TGFα RNA was measured using quantitative real time PCR. **(F)** JM6 cells were treated with 1nM E_2 alone or in presence of increasing concentration of indicated TPEs and SERMs. **(A-E)** are represented as fold difference versus vehicle treated cells. Each data point is average +/- SD of three replicates.

Fig.6. Recruitment of ER alpha and SRC3 (AIB1) at PS2 proximal promoter region containing ERE in MCF7:WS8 and MCF7:5C cells. (A) Depiction of PS2 proximal promoter region and the ERE region relative to TSS (transcription start site). **(B)** MCF7:WS8 cells treated for 45 minutes with E_2 (1nM), 3OHTPE (1µM), EtOX (1µM), bisphenol (1µM) and 4OHT (1µM) and ChIP assay was performed as described in materials and methods. **(C)** MCF7:5C cells were treated identically as mentioned above and ChIP assay was performed under identical conditions. Data is represented as percent input of the starting chromatin used for the ChIP

Fig.7. Differential regulation of the ERα protein by planar and non-planar estrogens. **(A)** MC2 **(B)** JM6 **(C)** MCF7:WS8 **(D)** MCF7:5C cells were treated with E_2 (1nM), DES (1nM), equilin (1nM), estrone (1nM), equilenin (1nM), 3OHTPE (1µM), EtOX (1µM), bisphenol (1µM), 4OHT (1µM), endox (1µM), baze (1µM), ral (1µM) and cell lysates were analysed by western blotting by anti ERα antibody. Blot was reprobed by anti actin antibody.

Fig.8. The binding site of ERα with different ligands. The ligands are depicted with their corresponding grid molecular surfaces colored in gray. Also, Leu525 and Leu540 are depicted as grid molecular surfaces colored in blue. **(A)** Agonist conformation of ERα with E_2 (depicted in

magenta; PDB code: 1GWR). **(B)** Antagonist conformation of ERα with 4OHT (colored in green; PDB code: 3ERT). **(C)** Docking of bisphenol in agonist conformation (colored in cyan; PDB code: 1GWR). **(D)** Docking of bisphenol in antagonist conformation (colored in cyan: PDB code: 3ERT).

Figure 1

Figure 1

		Complex Conformation	Action	Result and Extrapolated Interpretation		Mutant ER Assay at TGFα Gene
A.	Type I Estrogen Planar		Helix 12 seals LBD so AF2 coactivators bind. D351 under helix 12. TGFα gene activation	Full estrogen action Growth + Apoptosis		Full Estrogen Action
B.	Type II Estrogen Angular TPE		Helix 12 pushed back AF2 reduced less coactivator binding. D351 exposed. TGFα gene active.	Differential estrogen action Growth + Delayed Apoptosis		No Estrogen Action
C.	Nonsteroidal Antiestrogens TPE Based		Helix 12 pushed back. AF2 reduced coactivator binds. D351 exposed. Tamoxifen activates TGFα gene.	No estrogen action with no growth or apoptosis.		No Estrogen Action

Figure 2

(A)

17β Estradiol (E$_2$)

Diethylstilbestrol(DES)

Equilin

Estrone

Equilenin

(B)

Bisphenol

Trihydroxytriphenylethylene (3OHTPE)

Ethoxytriphenylethylene (EtOX)

(C)

4-Hydroxytamoxifen (4OHT)

Endoxifen (endox)

Raloxifene (ral)

Bazedoxifene (baze)

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

(A)

MC2

Veh | E2 | DES | Equilin | Estrone | Equilenin | ICI

ER-α

β-actin

Veh | E2 | Bisphenol | 3OHTPE | EtOX | 4OHT | endox | baze | ral

ER-α

β-actin

(B)

JM6

Veh | E2 | DES | Equilin | Estrone | Equilenin | ICI

ER-α

β-actin

Veh | E2 | Bisphenol | 3OHTPE | EtOX | 4OHT | endox | baze | ral

ER-α

β-actin

(C)

MCF7:WS8

Veh | E2 | DES | Equilin | Estrone | Equilenin | ICI

ER-α

β-actin

Veh | E2 | Bisphenol | 3OHTPE | EtOX | 4OHT | endox | baze | ral

ER-α

β-actin

(D)

MCF7:5C

Veh | E2 | DES | Equilin | Estrone | Equilenin | ICI

ER-α

β-actin

Veh | E2 | Bisphenol | 3OHTPE | EtOX | 4OHT | endox | Baze | ral

ER-α

β-actin

Figure 8

(A) Estradiol ERα complex

(B) 4-hydroxytamoxifen ERα complex

(C) Bisphenol in ERα structure

(D) Bisphenol in 4-OHT structure